Niti Aayog recommends a standard pharmaceutical chapter for all future FTA negotiations.
The proposed model aims to reduce compliance costs and address non-tariff trade barriers.
India seeks to increase focus on high-value sectors like biologics and biosimilars.
Current R&D investment by domestic firms trails behind international benchmarks of 15-20 percent.